| Literature DB >> 28790929 |
Monique E Francois1, Cody Durrer1, Kevin J Pistawka2, Frank A Halperin2, Courtney Chang1, Jonathan P Little1.
Abstract
Background: High-intensity interval training (HIIT) can improve several aspects of cardiometabolic health. Previous studies have suggested that adaptations to exercise training can be augmented with post-exercise milk or protein consumption, but whether this nutritional strategy can impact the cardiometabolic adaptations to HIIT in type 2 diabetes is unknown. Objective: To determine if the addition of a post-exercise milk or protein beverage to a high-intensity interval training (HIIT) intervention improves cardiometabolic health in individuals with type 2 diabetes. Design: In a proof-of-concept, double-blind clinical trial 53 adults with uncomplicated type 2 diabetes were randomized to one of three nutritional beverages (500 mL skim-milk, macronutrient control, or flavored water placebo) consumed after exercise (3 days/week) during a 12 week low-volume HIIT intervention. HIIT involved 10 X 1-min high-intensity intervals separated by 1-min low-intensity recovery periods. Two sessions per week were cardio-based (at ~90% of heart rate max) and one session involved resistance-based exercises (at RPE of 5-6; CR-10 scale) in the same interval pattern. Continuous glucose monitoring (CGM), glycosylated hemoglobin (HbA1c), body composition (dual-energy X-ray absorptiometry), cardiorespiratory fitness ([Formula: see text]), blood pressure, and endothelial function (%FMD) were measured before and after the intervention.Entities:
Keywords: blood pressure; body composition; dairy; endothelial function; exercise; glycemic control; lifestyle
Year: 2017 PMID: 28790929 PMCID: PMC5524835 DOI: 10.3389/fphys.2017.00528
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Baseline characteristics of participants.
| Sex | 11 F | 12 F | 11 F |
| Age (y) | 62 ± 8 | 56 ± 9 | 55 ± 9 |
| BMI (kg/m2) | 36 ± 7 | 35 ± 6 | 33 ± 6 |
| Years of diagnosis | 6 ± 6 | 7 ± 7 | 5 ± 6 |
| Lifestyle only | 5 | 5 | 3 |
| Metformin | 10 | 11 | 13 |
| Sulfonylureas | 6 | 1 | 3 |
| SGLT2 inhibitors | 1 | 2 | 3 |
| DPP4 inhibitors | 1 | 2 | 3 |
| GLP1 analogs | 1 | 2 | 0 |
| Lipid lowering | 9 | 7 | 7 |
| Antihypertensive | 7 | 6 | 8 |
| LTPA score | 17 ± 15 | 14 ± 10 | 21 ± 17 |
| MVPA (min/day) | 14 ± 15 | 13 ± 13 | 30 ± 19 |
| Dairy intake (servings/day) | 2.3 ± 2.4 | 2.7 ± 2.1 | 2.1 ± 1.6 |
F, Females; LTPA, Leisure-Time Physical Activity; MVPA, Moderate-Vigorous Physical Activity.
Figure 1Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
Figure 2Continuous blood glucose across 24-h (n = 48) before and after the intervention (groups collapsed, *main effect of time: p = 0.01). Inset: Change in blood glucose after the intervention in the milk, protein, and water groups.
Body composition, cardiorespiratory fitness, blood pressure, flow-mediated dilation, triglycerides, C-reactive protein, and glycemic control measures before and after 12 weeks of HIIT and nutritional beverage.
| Mass (kg) | 97.7 ± 19.3 | 96.8 ± 20.5 | 95.9 ± 17.3 | 94.5 ± 17.3 | 89.5 ± 21.1 | 89.1 ± 20.9 | 0.46 | 0.03 |
| VAT (g) | 1057 ± 335 | 1033 ± 316 | 1007 ± 260 | 981 ± 212 | 815 ± 337 | 802 ± 285 | 0.75 | 0.25 |
| 1.7 ± 0.4 | 2.0 ± 0.7 | 1.8 ± 0.5 | 2.0 ± 0.6 | 1.9 ± 0.5 | 2.1 ± 0.5 | 0.53 | <0.01 | |
| HbA1c (%; mmol/mol) | 7.1 ± 0.8 | 6.9 ± 0.7 | 6.9 ± 0.8 | 7.0 ± 0.7 | 6.9 ± 0.8 | 6.6 ± 0.9 | 0.92 | <0.01 |
| 54 ± 9 | 52 ± 8 | 54 ± 8 | 53 ± 8 | 51 ± 8 | 49 ± 9 | |||
| Fasting glucose (mmol/L) | 8.6 ± 2.3 | 8.3 ± 1.7 | 9.2 ± 1.9 | 9.5 ± 2.3 | 8.9 ± 2.7 | 8.5 ± 2.1 | 0.35 | 0.53 |
| Triglycerides (mg/dL) | 149 ± 82 | 152 ± 70 | 161 ± 62 | 139 ± 65 | 152 ± 93 | 142 ± 80 | 0.36 | 0.17 |
| C-reactive protein (mg/dL) | 7.1 ± 10.3 | 4.4 ± 5.3 | 4.7 ± 4.3 | 4.9 ± 4.7 | 3.7 ± 4.1 | 3.1 ± 3.6 | 0.33 | 0.21 |
| 24-h mean (mmol/L) | 8.4 ± 1.4 | 7.7 ± 1.2 | 8.1 ± 1.4 | 7.8 ± 1.7 | 8.4 ± 2.1 | 7.8 ± 1.5 | 0.74 | 0.01 |
| SD (mmol/L) | 1.6 ± 1.0 | 1.3 ± 0.5 | 1.6 ± 0.6 | 1.1 ± 0.4 | 1.7 ± 0.8 | 1.5 ± 0.7 | 0.51 | 0.01 |
| MAGE (mmol/L) | 4.3 ± 3.5 | 3.1 ± 1.3 | 4.1 ± 2.0 | 2.8 ± 1.3 | 4.1 ± 2.2 | 3.7 ± 1.6 | 0.60 | 0.02 |
| Systolic (mmHg) | 130 ± 10 | 119 ± 7 | 132 ± 13 | 129 ± 9 | 128 ± 13 | 117 ± 11 | 0.03 | <0.01 |
| Diastolic (mmHg) | 79 ± 6 | 75 ± 5 | 83 ± 11 | 79 ± 6 | 81 ± 7 | 75 ± 7 | 0.20 | <0.01 |
| Absolute FMD (mm) | 0.020 ± 0.01 | 0.027 ± 0.01 | 0.018 ± 0.01 | 0.024 ± 0.01 | 0.019 ± 0.01 | 0.023 ± 0.01 | 0.61 | <0.01 |
| Baseline diameter (mm) | 0.41 ± 0.10 | 0.41 ± 0.09 | 0.41 ± 0.08 | 0.41 ± 0.07 | 0.41 ± 0.07 | 0.42 ± 0.07 | 0.77 | 0.71 |
| Time to peak (s) | 64 ± 26 | 57 ± 25 | 60 ± 30 | 46 ± 23 | 56 ± 21 | 50 ± 21 | 0.75 | 0.05 |
| Total energy intake (Kcal/day) | 2053 ± 881 | 2039 ± 898 | 1810 ± 525 | 2017 ± 706 | 1912 ± 629 | 1888 ± 710 | 0.35 | 0.25 |
HbA.
Time effect p < 0.05.
Interaction group.
Figure 3Change from pre intervention for (A) % body fat, (B) lean body mass, (C) cardiorespiratory fitness () and (D) glycosylated hemoglobin (HbA1c) in the milk, protein, and water groups (all main effect of time p < 0.05, no group interaction p > 0.05).
Figure 4Data for (A) mean arterial blood pressure (MAP), (B) percentage flow-mediated dilation (%FMD), and (C) waist circumference, before (Pre), after 6 weeks (Mid), and 12 weeks (Post) mean for all participants (bar graph, all main effect of time p < 0.05) and individual data (line and symbols per beverage group, no group interaction p > 0.05).